NYSE: ANVS · Life Sciences · 7 alerts · CIK 1477845
Share price
$0.7500Close, Nov 16
Market cap
$46.5M
Shares outstanding
62.02MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834
Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Annovis Bio, Inc. filings on SEC EDGAR ↗
Annovis Bio entered into an underwriting agreement to raise approximately $21.0 million through a public offering of 19,000,000 shares of common stock and 2,000,000 pre-funded warrants, accompanied by warrants to purchase an additional 21,000,000 shares. The company intends to use the proceeds for the clinical development of its lead compound, Buntanetap, in studies for Alzheimer’s and Parkinson’s disease.
Annovis Bio received a deficiency notice from the NYSE for failing to maintain a minimum average market capitalization of $50 million and stockholders' equity of $50 million over a 30-day period. The company has 45 days to submit a compliance plan and 9 months to regain compliance to avoid delisting. During this period, the stock will continue to trade under the symbol 'ANVS' with an added '.BC' designation.